CARDIFF ONCOLOGY, INC. Stock Issued During Period, Value, Other
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CARDIFF ONCOLOGY, INC. stock issued during period, value, other for the quarter ending 2020-06-30 was -$8.00K.
- CARDIFF ONCOLOGY, INC. stock issued during period, value, other for the quarter ending 2019-03-31 was -$40.00K.
- CARDIFF ONCOLOGY, INC. stock issued during period, value, other for fiscal 2020 was -$8.00K.
- CARDIFF ONCOLOGY, INC. stock issued during period, value, other for fiscal 2019 was -$40.00K.
| Period end | Stock Issued During Period, Value, Other 3 month | Stock Issued During Period, Value, Other 12 month |
|---|---|---|
| 2020-12-31 | -$8.00K 10-K · filed 2022-02-24 | |
| 2020-06-30 | -$8.00K 10-Q · filed 2021-11-04 | |
| 2019-12-31 | -$40.00K 10-K · filed 2021-02-25 | |
| 2019-03-31 | -$40.00K 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |